1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
HeartBeam, Inc.

HeartBeam, Inc.

BEATW
HeartBeam, Inc.US flagNASDAQ Capital Market
0.02
USD
-0.01
- -
13.42MMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-1
-1
-4
-13
-15
-19
-21
-20
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
-5
13
2
16
1
1
-1
LT Debt
3
- -
- -
- -
- -
- -
- -
- -
Total Equity
-4
-5
13
2
16
2
3
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
34
40
41
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
2
5
2
Cash, Cash Equivalents & STI
2
4
2
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
3
3
Payables & Accruals
2
3
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
15.3%
57.38%
Free Cash Flow
- -
137.74%
-0.57%
Net Income, GAAP
- -
112.24%
8.06%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Branislav Vajdic
Full Time Employees
16
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Address
2118 Walsh Avenue Santa Clara CA United States of America 95050
IPO Date
Nov 11, 2021
CIK
0001779372
Website
heartbeam.com
Similar Companies
EGF Theramed Health Corp. (TMED.CN)
Pro Medicus Limited (PMCUF)
NextGen Healthcare, Inc. (QY1.F)
Cloud DX Inc. (CDX.V)
TrivarX Limited (TRI.AX)
SomaLogic, Inc. (SLGC)
Business
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company that develops and commercializes ambulatory electrocardiogram (ECG) solutions for detecting and monitoring cardiac conditions inside and outside healthcare facilities. The company offers the HeartBeam AIMIGo, a credit card-sized, cable-free device that captures ECG signals in three non-coplanar dimensions using proprietary Vector Electrocardiography (VECG) technology and synthesizes them into a 12-lead ECG; the HeartBeam AIMI platform, a cloud-based diagnostic software system with AI-powered analysis for heart attack detection and arrhythmia assessment; and related telehealth services enabling physicians to track cardiac trends and direct patient care remotely. HeartBeam holds over 20 issued patents supporting its 3D ECG platform and targets high-risk cardiovascular patients, cardiologists, hospitals, and clinics primarily in the United States. Founded in 2015 and headquartered in Santa Clara, California, the company operates in the healthcare equipment and services sector. HeartBeam received FDA 510(k) clearance for its 3D ECG technology for arrhythmia assessment in December 2024 and continues to pursue clearance for its 12-lead ECG synthesis software, with recent FDA feedback prompting updates to its regulatory path as of November 2025. In October 2025, HeartBeam announced a strategic partnership with HeartNexus, Inc., to provide 24/7 cardiology reader services integrating its device with on-demand cardiologist interpretations for patients experiencing symptoms like palpitations. The company is evaluating commercialization of its cleared 3D ECG system and plans enhancements to its ecosystem, including AI wellness features, community tools, and wearable integrations, ahead of anticipated full product launches.

Company News

APIChatGPT

  • defenseworld.net

    HeartBeam (NASDAQ:BEATW) Shares Down 3.1% – Here’s What Happened

  • defenseworld.net

    HeartBeam (NASDAQ:BEATW) Stock Price Up 73.7% – Here’s Why